owering Of Very long chain fatty Acids in patients with X-linked adrenoleukodystrophy: a biochemical study

Completed

• Conditions: X-linked adrenoleukodystrophy (X-ALD); Nervous System Diseases; Adrenoleukodystrophy

• Registration Number: ISRCTN31565393
• Lead Sponsor: Academic Medical Centre (AMC) (Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-11-22
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

1. Male patients with X-ALD (confirmed by biochemical analysis or mutation analysis of the ABCD1 gene)
2. 18 years or older
3. Able to give informed consent and visit the hospital
4. No contraindications for use of trial medication

Exclusion Criteria

1. Use of another cholesterol lowering drug
2. Liver disease or creatine kinase (CK) more than three times baseline level
3. Use of very long chain fatty acid lowering therapy (e.g. Lorenzo's oil) in the eight weeks preceding the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Very long chain fatty acid levels (in plasma and erythrocytes).

Secondary Outcome Measures

Name	Time	Method
o secondary outcome measures